Research Article
Citrus Flavone Tangeretin Inhibits CRPC Cell Proliferation by Regulating Cx26, AKT, and AR Signaling
Figure 3
Tangeretin could synergistically inhibit the proliferation and migration of castration-resistant prostate cancer cells when combined with cisplatin or sorafenib under serum deprivation conditions. (a) Tangeretin can synergistically reduce the viability of C4-2 cells when treated alongside sorafenib in serum-free conditions. (b) Tangeretin can also synergistically reduce the viability of C4-2 cells when combined with cisplatin under serum deprivation conditions. (c) Tangeretin can synergistically reduce the cell viability of Du145 cells when combined with cisplatin in serum-free conditions. (d) Tangeretin can significantly inhibit colony formation by C4-2 cells synergy when combined with sorafenib. (e) Tangeretin can significantly inhibit the migration of C4-2 cells (×200). (f) Tangeretin can significantly inhibit the migration of Du145 cells, whilst also synergistically inhibiting their migration when combined with sorafenib under reduced serum conditions (×200). compared with the control or the 0 group. Tan, tangeretin and CDDP, cisplatin.
(a) |
(b) |
(c) |
(d) |
(e) |
(f) |